NRx Pharmaceuticals’ ketamine ANDA amendment reclassified as minor, GDUFA date set for November 10, 2026
AI Summary- NRx Pharmaceuticals received FDA notice reclassifying its ketamine ANDA amendment as minor.
- November 10, 2026 became the revised GDUFA goal date.
- FDA cited no substantial resource expenditure for the reclassified amendment.